Tiotropium bromide is a once-daily anticholinergic recommended for maintenance treatment of chronic obstructive pulmonary disease. The 24-h bronchodilation in patients with chronic obstructive pulmonary disease achieved with tiotropium treatment is currently unique. However, there is an increasing demand for proven efficacy in parameters of more direct interest to patients, in addition to physiological parameters. This article reviews the data currently available on the efficacy of tiotropium to improve the health-related quality of life of patients with chronic obstructive pulmonary disease.
|Number of pages||15|
|Journal||Expert Review of Pharmacoeconomics & Outcomes Research|
|Publication status||Published - 1 Aug 2006|